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OBJECTIVES In the current study, we hypothesized that beraprost would: 1) improve treadmill exercise
performance and quality of life; and 2) decrease rates of ischemic events in patients with
intermittent claudication.
BACKGROUND Previous trials with beraprost sodium, an orally active prostaglandin I2 analogue, in the
treatment of claudication in patients with peripheral arterial disease (PAD) have been
inconsistent.
METHODS Patients with intermittent claudication (n  897) were randomized to receive either 40 g
three times a day of beraprost with meals (n 385) or placebo (n 377) in a double-blinded
manner for one year. The primary efficacy parameter was treadmill-measured maximum
walking distance, as assessed at three and six months after randomization. Secondary efficacy
parameters included treadmill-measured pain-free walking distance and change in quality of
life.
RESULTS There was no significant improvement in maximum walking distance in the beraprost group
(16.7%) as compared with the placebo group (14.6%, p  NS). Administration of beraprost
did not improve the pain-free walking distance (p  NS between treatment groups), and
there was no improvement in the quality-of-life measures between the treatment groups. The
incidence of critical cardiovascular events was 7.3% in the beraprost group and 11.4% in the
placebo group (p  NS). There was a significant reduction in the combination of
cardiovascular death and myocardial infarction in the beraprost group (p  0.01).
CONCLUSIONS Despite previous investigations suggesting efficacy, these results indicate that beraprost is not
an effective treatment to improve symptoms of intermittent claudication in patients with
PAD. The potential benefit of beraprost on critical cardiovascular events would require
confirmation in a larger prospective investigation. (J Am Coll Cardiol 2003;41:1679–86)
© 2003 by the American College of Cardiology Foundation
Peripheral arterial disease (PAD) is a common condition in
the U.S., with an estimated prevalence of 12% in the general
population; PAD has been estimated to affect 8 million
Americans (1). It is also common in primary care office
practices and is present in 29% of patients 70 years of age
See page 1687
or 50 years of age with a history of smoking or diabetes
(2). In this office-based population, up to 24% of subjects
may suffer claudication symptoms, as defined by their
physicians (2). These claudication symptoms are associated
with a marked impairment in quality of life (QOL).
Improvement of claudication symptoms can be accom-
plished by prescription of supervised exercise rehabilitation
(Anonymous, Current Procedural Terminology [CPT],
2001. Unpublished data) (3), use of claudication pharma-
cotherapies (4,5), or selective use of revascularization strat-
egies (6). There are currently two medications approved by
the U.S. Food and Drug Administration (FDA) approved
for the relief of claudication: pentoxifylline (Trental) and
cilostazol (Pletal) (7). Whereas pentoxifylline has demon-
strated limited therapeutic efficacy, cilostazol has consis-
tently been shown in multiple prospective clinical trials to
improve exercise performance and QOL in patients with
claudication (8–10). It is notable that neither medication
has been prospectively evaluated for its ability to decrease
cardiovascular ischemic events. Despite current therapeutic
choices to treat claudication, there remain many patients
who do not respond adequately to current pharmacothera-
pies, who may not be amenable to participation in exercise
programs, or whose limb arterial anatomy or procedural
risk/benefit ratio is unfavorable for revascularization. Thus,
a large population of patients with claudication would
benefit from the availability of additional orally active
therapeutic agents that could further diminish claudication
symptoms and whose pharmacologic profile might decrease
cardiovascular event rates.
Prostaglandin I2 (PGI2), or prostacyclin, is produced by
endothelial cells and has such a promising pharmacologic
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profile. This naturally occurring prostanoid relaxes vascular
smooth muscle (11,12), inhibits platelet aggregation
(11,12), and also suppresses vascular smooth muscle prolif-
eration (13). Beraprost sodium is an orally active PGI2
analogue that elicits vasodilating and antiplatelet properties
in vivo (14,15).
The Beraprost et Claudication Intermittente study
(BERCI-2) (16) demonstrated that both maximum walking
distance (MWD) and pain-free walking distance (PFWD)
were increased significantly in patients receiving beraprost
sodium. However, another trial of beraprost that evaluated
330 patients with claudication showed no significant im-
provement in MWD (17). These inconsistent trial efficacy
outcomes led to the design of the current investigation. We
hypothesized that treatment with beraprost would improve
measures of walking distance and community-based func-
tional status.
METHODS
Trial design. The current investigation was a randomized,
double-blinded, multicenter, placebo-controlled trial con-
ducted at sites in the U.S. Patients underwent a single-
blinded, placebo run-in phase after which they were ran-
domly assigned to receive 40 g three times a day (TID) of
beraprost with meals or placebo for one year. Although the
primary efficacy end point was treadmill walking distance
after six months of treatment, the treatment was continued
for one year to assess safety. The protocol was approved by
the ethical committees of the respective institutions partic-
ipating in the study, and each patient offered written,
informed consent.
Outcomes. The primary claudication efficacy outcome of
the trial was MWD on a treadmill at 24 weeks. Maximum
walking distance (recorded in feet) was defined as the
distance walked until the patient was forced to stop from
maximum claudication pain. The principal reinforcing out-
come measure was the change in PFWD, defined as the
distance walked before the onset of pain. The secondary end
points included subjective walking distance, as assessed by
the Walking Impairment Questionnaire (WIQ), a health-
related QOL questionnaire (short-form 36 [SF-36]), a
change in the ankle-brachial index (ABI), and the incidence
of critical cardiovascular events, as defined subsequently. A
“responder profile” was defined “pre hoc” as any patient with
a 35% increase in the treadmill-derived PFWD, com-
pared with baseline (day of randomization), at six months,
and in the absence of critical cardiovascular events, and was
considered a secondary outcome.
Quality of life was assessed using previously validated
questionnaires, the SF-36, and the WIQ measured at run-in
day 14 (baseline) and weeks 12 and 24 (18). Critical
cardiovascular events were defined as death of cardiovascular
origin (confirmed or sudden death), nonfatal myocardial
infarction, or unstable angina; stroke or transient ischemic
attack; and critical leg ischemia (rest pain necessitating
urgent medical intervention or a surgical procedure to avoid
amputation), subacute critical ischemia (continuous rest
pain for 2 weeks requiring analgesics), peripheral angio-
plasty, peripheral bypass surgery, or amputation at any level.
All critical cardiovascular events were adjudicated by an
independent Critical Cardiovascular Events Committee.
Patient selection. Patients were included if they were
between 40 and 80 years of age, with stable, intermittent
claudication for longer than six months. They were also
required to have a rest ABI 0.90, with a 10 mm Hg
decrease in ankle pressure 1 min after completing the
exercise treadmill test; PFWD on a standardized treadmill
test 164 feet (50 m) but 984 feet (300 m) at the
screening visit; and PFWD variability 25% between the
tests performed during the run-in phase.
Patients were excluded from the study if they had critical
limb ischemia (defined as the presence of rest pain requiring
analgesics 2 weeks or the presence of lower limb ulcers or
gangrene); underwent coronary artery or peripheral artery
angioplasty or surgical limb arterial bypass within the last
three months; were anticipated to require surgical or per-
cutaneous revascularization within six months of random-
ization; or were currently participating in a supervised
exercise regimen. Exclusion was also mandated for patients
who had a stroke or myocardial infarction or deep-vein
thrombosis within the last three months; nonatherosclerotic
PAD (e.g., thromboangiitis obliterans); a known abdominal
aortic aneurysm 4.5 cm; unstable angina pectoris within
the last three months; heart failure (New York Heart
Association functional class III or IV); severe, uncontrolled
hypertension (systolic blood pressure 180 mm Hg or
diastolic blood pressure95 mm Hg); anemia (hemoglobin
10 g/dl in women and 11 g/dl in men) or any clinically
significant bleeding episode within the last year; an abnor-
mal platelet count (platelets 150,000 mm3 or 60,000/
mm3). Additional exclusion criteria included type I diabetes
mellitus; morbid obesity (body mass index 40 kg/m2);
severe renal insufficiency (creatinine 2.5 mg/dl); severe
hepatic insufficiency (alanine transaminase and aspartate
transaminase 3 times the upper normal limit on two
separate tests); any disorder that would affect the interpre-
tation of treadmill test results; and any other life-
threatening disease or any psychiatric condition that would
impair either informed consent or compliance with the
Abbreviations and Acronyms
ABI  ankle-brachial index
BERCI-2  Beraprost et Claudication Intermittente study
MWD  maximum walking distance
PAD  peripheral arterial disease
PFWD  pain-free walking distance
PGI2  prostaglandin I2
QOL  quality of life
SF-36  short-form 36
TID  three times a day
WIQ  walking impairment questionnaire
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study protocol. Additional exclusion criteria included use of
cilostazol, pentoxifylline, or HeartBar (L-arginine) within
one month prior to the screening treadmill test; current use
of warfarin, heparin, or thrombolytic therapy; or any disease
state that could potentially decrease gastrointestinal absorp-
tion of the study medication. Patients using aspirin, clopi-
dogrel, or ticlopidine were not excluded from the study.
Study screening and procedures. The study protocol is
outlined in Figure 1. After provision of informed consent,
all patients underwent a full medical history, as well as
assessment of current lifestyle and atherosclerosis risk fac-
tors. The clinical examination included a full physical
examination, 12-lead electrocardiogram, clinical laboratory
tests, assessment of concomitant medications, and ABI
measurement. Patients then underwent a screening exercise
treadmill test, from which the PFWD and MWD were
recorded. The treadmill protocol utilized a constant grade
(10%) and speed from the onset of 1.9 mph (3 km/h). The
test was timed in minutes and seconds, and the elapsed time
was used to calculate the exact distance walked for PFWD
and MWD. The PFWD needed to be 164 feet but 984
feet. If the patient met the treadmill walking and selection
criteria, the placebo drug was dispensed and a single-
blinded run-in phase was begun.
During the placebo run-in phase, patient compliance was
assessed by a pill count, and compliance was mandated to
remain within 75% to 125% to permit continuation in the
protocol. Changes in any concomitant medications were
noted, and a baseline exercise treadmill test was performed
on day 7. Patients underwent another baseline exercise
treadmill test on day 14 of the run-in phase and were
eligible for randomization if the PFWD was within 25%
between the day 7 and day 14 values and all other criteria
were met. Patients who did not meet the claudication
distance criteria for the study were given the opportunity to
undergo a third baseline treadmill test on day 21 of the
run-in phase. Subsequent efficacy exercise treadmill tests
were then performed at weeks 6, 12, 18, and 24.
Statistical analysis. SAMPLE SIZE CONSIDERATIONS. The
effect of beraprost on MWD at week 24, as measured on a
fixed treadmill test, was the primary end point for this trial
and was the basis on which the sample size was estimated.
The results of the intention-to-treat analysis of treadmill
exercise tests in 422 PAD patients who received beraprost
for 24 weeks in a phase III study in Europe (BERCI-2)
were used as the basis of sample size estimates. The
treadmill test parameters and run-in phase PFWD inclusion
criteria in BERCI-2 were identical to those in this trial. In
Figure 1. Study design for this trial. The current study was prospective, randomized, and placebo-controlled, with identical outcome measures and treadmill
protocol as in the previously published BERCI-2 study (16). MWD  maximum walking distance; PFWD  pain-free walking distance; TID  three
times a day.
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BERCI-2, MWD increased by 65.8% for beraprost-treated
patients and by 38.7% for placebo-treated patients at 24
weeks. This corresponds to a treatment difference in natural
logarithms of log (165.8/138.7)  0.179; its standard error
of 0.048 corresponds to a standard deviation of0.5. Under
the assumption of an effect size of 0.18, a slightly larger
standard deviation of 0.54, an alpha level of 0.01, a
two-sided comparison of the null hypothesis in which the
mean values are equal, and a 95% power calculation, the
sample size based on the normal distribution calculation was
323 patients per group (n  [2.576  1.645]2  2 
[0.542]/[0.182]). Adjustment for using a nonparametric test
(assuming normal distributions) brought the sample size to
344 patients per group.
Data analysis. The primary end point was MWD, which
was not distributed normally and therefore was analyzed as
log-transform values (log [value/baseline], where log use
equals the natural algorithm). The results were thus pre-
sented as geometric mean values. Statistical significance was
determined at p  0.05. Data are presented as the mean
value  SEM. The incidence of the first cardiovascular or
critical event was analyzed by the log-rank test.
RESULTS
Beginning in the year 2000, 882 patients entered into the
three-week, single-blinded, run-in phase. Of these, 762
patients were randomized to receive beraprost or placebo in
the double-blinded, one-year study. Reasons for nonran-
domization included treadmill variability for PFWD 25%
during the run-in phase (n  37), withdrawal of consent (n
 26), abnormal laboratory results (n  22), protocol
violation (n  20), occurrence of an adverse event (n  12),
compliance failure (n  2), and loss to follow-up (n  1).
Thus, there were 385 patients in the beraprost group and
377 patients in the placebo group. The demographic data of
patients by treatment assignment are listed in Table 1. The
distribution of atherosclerosis risk factors, such as smoking,
dyslipidemia, hypertension, and diabetes mellitus, were
representative of patients with PAD and were not different
between the two groups (p  NS for each comparison).
Concomitant medications used by study patients included
angiotensin-converting enzyme inhibitors, calcium channel
blockers, nitrates, lipid-lowering drugs, oral antidiabetic
agents, and diuretics. The use of concomitant medications,
including aspirin (n  249 for placebo and n  244 for
beraprost), clopidogrel (n  21 for placebo and n  27 for
beraprost), and ticlopidine (n  3 for placebo and n  1 for
beraprost), was not different between the treatment groups.
Study medication withdrawal rates and adverse event
rates. Of the 762 patients who were randomized to receive
study medication in the double-blinded phase of the study,
a total of 113 patients (29%) discontinued treatment pre-
maturely, primarily due to anticipated prostanoid adverse
events (Table 2). Headache was more common in the
patients treated with beraprost versus placebo (27.5% vs.
5.0%, p 0.001). Vasodilation occurred more commonly in
the beraprost group than in the placebo group (13.5% vs.
4%, p  0.001). Diarrhea (7.3% vs. 1.3%), pain (5.5% vs.
1.1%), and nausea (4.4% vs. 1.3%) also occurred more
frequently in the beraprost group than in the placebo group
(p 0.02 for all). The most common adverse events leading
Table 1. Baseline Demographic Data by Treatment Group for Current Study and BERCI-2 Study
Current Study BERCI-2
Beraprost Placebo Beraprost Placebo
Age (yrs) 65.9 65.7 63.3 61.5
Male 306 (79%) 279 (74%) 85% 84%
Duration of claudication (yrs) 6.4 6.6 6.4 5.3
Previous surgery 88 (23%) 92 (24%) 28% 26%
Hypertension 282 (73%) 284 (75%) 41% 43%
Diabetes 111 (29%) 111 (29%) 18% 18%
Smoker
Current 127 (33%) 129 (34%) 34% 40%
Former 234 (61%) 217 (58%) 58% 51%
Dyslipidemia 270 (70%) 269 (71%) 43% 46%
ABI (before ETT) 0.64 0.65 0.73 0.71
MWD (feet) 538 560 901 888
PFWD (feet) 279 296 427 438
Data are presented as the mean value or number (%) of subjects. There was no difference between the treatment groups for either
the current study or BERCI-2 study. There was a higher percentage of patients with diabetes, hypertension, and dyslipidemia
in the current study, than in BERCI-2. The ABI, MWD, and PFWD were lower in the current study than in BERCI-2.
ABI  ankle-brachial index; ETT  exercise treadmill test; MWD  maximum walking distance; PFWD  pain-free
walking distance.
Table 2. Reasons for Discontinuation of Study Medication
Beraprost Group
(n  385)
Placebo Group
(n  377)
Died 1 (1%) 1 (1%)
Deterioration 13 (3%) 10 (3%)
Adverse events 57 (15%) 17 (5%)
Withdrew consent 25 (6%) 17 (5%)
Protocol violation 8 (2%) 5 (1%)
Lost to follow-up 9 (2%) 1 (1%)
Total 113 (29%) 51 (14%)
Data are presented as the number (%) of subjects.
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to discontinuation included headache and vasodilation
(8.6% and 3.9% in the beraprost group, respectively; p 
0.001 for both comparisons). There was no significant
difference in serious adverse events and compliance with
medication between the two groups.
Exercise treadmill results. There was no difference in the
primary efficacy parameter of mean MWD at baseline and
at week 24 between the treatment groups: 16.7% and 14.6%
for beraprost and placebo, respectively (Fig. 2). Also, there
was no significant change throughout the entire study for
the primary reinforcing end point of mean PFWD at week
24 between the treatment groups: 19.2% and 15.4% for
beraprost and placebo, respectively (p  0.24) (Fig. 2).
Figure 3 shows the percent change from baseline for MWD
and PFWD between the two treatment groups (p  NS).
When the data were analyzed according to a per-protocol
population (those patients who completed the entire 24
weeks of the study), there was no difference in the primary
and principal reinforcing end points between the two groups
(p  NS). Evaluation for clinical responders, defined as a
35% increase in MWD in the absence of any clinical
cardiovascular event, demonstrated no difference between
the groups. The measured response rate was 31% in the
active beraprost treatment group, compared with 33% in the
placebo group (p  0.75).
The ABI remained stable throughout the study and did
not differ between the two groups. There was also no
difference between the two groups regarding compliance
with study drug or tobacco consumption. There was no
interaction of the primary end point with other background
variables, such as hypertension, diabetes, smoking, and
dyslipidemia.
Quality-of-life outcomes. There was no significant differ-
ence in the QOL measures between the beraprost and
placebo groups at week 24. Specifically, the WIQ distance
and speed scores were unchanged from baseline to study
conclusion for distance and speed (p NS) in the beraprost
group. Similarly, the baseline and final SF-36-derived
physical component score was unchanged (47 vs. 50 and 50
vs. 51 for the beraprost and placebo groups, p  NS for
both comparisons). No differences in these QOL parame-
ters were observed between the treatment groups.
Critical cardiovascular event rates. Critical cardiovascular
events occurred in 28 patients treated with beraprost and 43
on placebo (Table 3). However, when the combination of
cardiovascular death and myocardial infarction were
counted separately, there were nine in the placebo group and
one in the beraprost group (p  0.01). This intriguing
difference in a single ischemic end point (numbers of fatal
and nonfatal myocardial infarctions between treatment
groups) cannot serve as the basis for conclusions regarding
the potential cardioprotective effect of beraprost, as the
combined primary critical cardiovascular end point was not
statistically different between the treatment cohorts.
Figure 2. Graph showing maximum walking distance (MWD) (top panel) and pain-free maximum walking distance (PFWD) (bottom panel) for
beraprost (diamonds) and placebo (squares). There was no significant difference in MWD and PFWD between beraprost and placebo.
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DISCUSSION
Prolonged oral administration of the PGI2 analogue bera-
prost over a period of six months did not improve any
objective or subjective measure of claudication symptoms in
this large, prospective trial. Specifically, MWD, PFWD,
the responder profile, and patient-reported measures of
walking impairment or QOL did not improve, compared
with placebo, in patients with intermittent claudication.
Although the current study demonstrated a nonsignificant
decrease in critical cardiovascular events (including fatal and
nonfatal systemic and limb events and revascularizations) in
beraprost-treated patients, there was a significant reduction
in the combination of cardiovascular death and myocardial
infarction in those patients assigned to beraprost.
These results are similar to a previous study, also con-
ducted in the U.S., of beraprost evaluated in 330 patients
with claudication (17). In this previous study, patients were
randomized to placebo or oral beraprost over a dose range of
30, 60, or 90 g twice daily. After three months, there were
no differences in MWD measured on a graded treadmill
protocol or in MWD measured on a constant-load treadmill
protocol. Thus, the total U.S. experience with beraprost in
claudication in clinical trials totals over 1,100 patients. This
trial and that one (17) have failed to provide any evidence of
efficacy by measures of either treadmill exercise performance
(using two different validated protocols) or disease-specific
or general QOL.
The estimated half-life of this compound is 45 min,
with linear pharmacokinetic characteristics at doses ranging
from 20 to 60 g TID. The effect of beraprost on walking
distance in patients with intermittent claudication was
assessed in the BERCI dose-effect study (19). In this
Figure 3. Graph showing percentage change from baseline in MWD (top panel) and PFWD (bottom panel) for beraprost (diamonds) and placebo
(squares). There was no significant difference in MWD and PFWD between beraprost and placebo. Abbreviations as in Figure 2.
Table 3. Critical Cardiovascular Events in Intention-to-Treat
Population
Event Beraprost Placebo
Cardiovascular death 1 4
Myocardial infarction 0 5
Unstable angina 5 7
Cardiovascular revascularization 7 7
Cerebrovascular accident 5 4
Worsening limb ischemia 6 8
Limb revascularization 4 8
Limb amputation 0 0
Total events 28 43
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double-blinded, randomized, multicenter, placebo-controlled
trial, beraprost was shown to increase the PFWD, compared
with placebo, at doses of 20 and 40 g TID, but not at 60 g.
From these data, the 40-g TID dose was tested in a
subsequent phase II trial—BERCI-2 (16). This study also
demonstrated that both MWD and PFWD were increased
significantly in patients receiving beraprost sodium.
The results of the two U.S. beraprost studies are in
contrast to the European BERCI-1 and BERCI-2 study
outcomes, which demonstrated significant improvements in
both PFWD and MWD, as well as QOL, over six months
of drug administration (16). A significant difference be-
tween the two U.S. trials was the administration of bera-
prost TID, which was designed to minimize the peak blood
levels and minimize study dropout from anticipated prosta-
noid adverse effects. The current trial was purposefully
designed to follow an identical study design as that of
BERCI-2 to facilitate a comparison of the results in these
two populations. Both trials enrolled a similar number of
patients and utilized a comparable formulation of beraprost;
nevertheless, the distinct study outcome is striking. Al-
though the current trial did not reproduce the BERCI-2
claudication improvement, the BERCI-2 cohort that re-
ceived beraprost also suggested a trend toward decreased
critical cardiovascular events in the beraprost-treated pa-
tients as compared with those assigned to placebo (4.8% in
the beraprost group and 8.9% in the placebo group, p 
NS). However, the total number of cardiovascular events
was relatively low in each of these trials, and therefore,
differences can only be regarded as hypothesis-generating.
Analysis of variables that might underlie such differing
study outcomes is important to assure that conclusions
regarding potential therapeutic efficacy or futility are poten-
tially elucidated. These two large, prospective investigations
differ in their study locations, and such geographic distinc-
tions may be associated with enrollment of heterogeneous
study cohorts, with potentially differing disease etiologies,
PAD severity, use of concomitant treatments, or application
of study outcome measurement techniques.
A comparison of the baseline demographic characteristics
between the two trials is shown in Table 1. There was no
significant difference in age, gender, duration of PAD, baseline
claudication distance, or previous limb bypass surgery rates
between the two studies. However, the current U.S. trial did
include a higher number of patients with hypertension, diabe-
tes, and lipid disorders, as compared with the BERCI-2 trial,
and may explain the failure to show efficacy in the present
study. It is unknown whether this might affect prostaglandin
absorption, distribution, or efficacy of this particular prosta-
glandin formulation. Also, the baseline ABI and walking
distance were somewhat lower in the current study, as com-
pared with the BERCI-2 trial, which may have affected the
outcome. Thus, it is possible that differences in the results
between the two trials may have been slight differences in
baseline demographics between the populations.
Although a lack of efficacy in any oral drug trial can also
be surmised to be due to impaired delivery of drug, we
consider this to be unlikely, as the adverse effect profile of
our subjects strongly indicated that patients randomized to
beraprost treatment reported symptoms strongly suggestive
of prostaglandin vasodilator effects. We also note that the
short half-life of orally administered prostaglandins has long
been hypothesized to limit their clinical efficacy in other
vascular disease states. This limitation may well be magni-
fied during treatment of claudication, in which the increased
metabolic demand of limb muscles during ambulation
usually requires a profound and sustained improvement in
limb blood flow or muscle metabolic function to be associ-
ated with an improvement in claudication symptoms.
Conclusions. The current trial results are in concordance
with previous U.S. data and demonstrate that prolonged
treatment with oral beraprost does not diminish the symp-
toms of claudication or improve the QOL of patients with
PAD. Whether the use of a more sustained prostaglandin
moiety might provide convincing data and proof of efficacy,
or whether there are more specific cohorts of patients with
PAD that might benefit from prostaglandin use, will require
a more precise understanding of the pathophysiology of
claudication itself. The potential benefit of beraprost on
critical cardiovascular events would require evaluation in a
larger, prospective investigation.
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